Table 1.
Patient characteristics and onco-surgical treatments
| Reference | Period | Population (conversion surgery) | Median - age |
Unresectable criteria |
Chemotherapy | Surgery | Lymphadenectomy (D2 or more) | Ro | |||||
| P1 | H1 | Cy1 | PAN/N3 | T4 | Other | ||||||||
| Nakajima et al[73], 1997 | 1989-1995 | 30 (19) | 53 | 9 (30%) | 11 (37%) | 23 (77%) | 8 (27%) | 3 (10%) | FLEP | NS | NS | 9 (30%) | |
| Yano et al[74], 2002 | May 1994-Dec 1999 | 34 (14) | 54.4 (31-73) | 26 (76%) | 4 (12%) | 10 (3.4%) | 12 (35%) | 1 (0.3%) | FEMTXP or THP-FLPM | NS | NS | 8 (24%) | |
| Satoh et al[75],2012 | May 2003-Mar 2008 | 51 (44) | 63 (35-79) | 24 (49%) | 3 (6%) | 12 (23%) | 7 (14%) | 5 (10%) | S1 + Cisplatin | TG (58%) | 82% | 26 (51%) | |
| DG (21.5%) | |||||||||||||
| Kanda et al[76],2012 | Apr 2000-Mar 2008 | 31(28) | 65.5 (49-79) | 7 (25%) | 4 (14.3%) | 15 (54%) | 9 (32%) | S1 + Cisplatin or Paclitaxel or Irinotecan | TG (42.89%) | 96.30% | 26 (93%) | ||
| DG (57.1%) | |||||||||||||
| Han et al[77], 2014 | Jan 2000-Dec 2009 | 34 (34) | 56 (28-71) | 7 (14%) | 5 (10%) | 15 (29.4%) | 7 (14%) | 5-FU + Platinum or 5-FU + Platinum + Taxane | NS | NS | 26 (76.5%) | ||
| Kim et al[78], 2014 | Jan 2003-Dec 2012 | 43 (18) | 52.8 (32-72) | 43 (100%) | 5-FU + Cisplatin or S1 + Cisplatin | TG (72.2%) | 100% | 10 (55%) | |||||
| DG (27.7%) | |||||||||||||
| Fukuchi et al[79], 2015 | Feb 2003-Dec 2013 | 151 (40) | 66 (31-79) | 11 (28%) | 5 (13%) | 3 (8%) | 6 (15%) | 26 (65%) | S1 + Cisplatin or S1 + Paclitaxel | TG (72.5%) | NS | 32 (80%) | |
| DG (27.5%) | |||||||||||||
| Kinoshita et al[80], 2015 | Apr 2006-Mar 2012 | 57 (34) | 65 (30-78) | 15 (26%) | 18 (32%) | 23 (40%) | 2 (3.5%) | DCS | TG (64.7%) | 50% | 27 (79%) | ||
| DG (26.5%) | |||||||||||||
| Sato et al[81], 2017 | Dec 2002-Apr 2014 | 100 (33) | 63 (26-78) | 33 (33%) | 29 (29%) | 61 (61%) | 14 (14%) | 11 (11%) | DCS I line, CPT-11 II line | TG (84.8%) | 100% | 28 (85%) | |
| DG (12.1%) | |||||||||||||
| Einama et al[82],2017 | Jan 2009-Dec 2015 | 10 | 70.5 (59-86) | 3 (30%) | 1 (10%) | 1 (10%) | 4 (40%) | 1 (10%) | S1 + CDDP or DOC | TG (40%) | 100% | 10 (100%) | |
| DG (30%) | |||||||||||||
| Mieno et al[83],2017 | Oct 2006-Dec 2012 | 31 (31) | 63 (35-78) | 25% | 16% | 58% | 26% | DCS + DS (Docetaxel-S1) in responder patients | TG (74.2%) | 77% | 23 (74%) | ||
| DG (22.6%) | |||||||||||||
| Yamaguchi et al[84], 2017 | 2001-2013 | 259 (84) | 61.7 (21-78) | 35 (41%) | 37 (44%) | 34 (40%) | DCS or S1 or S1 + Cisplatin or S1 + Taxane | TG (82.1%) | NS | 43 (51%) | |||
| DG (17.9%) | |||||||||||||
| Morgagni et al[85], 2018 | Apr 2005-Aug 2016 | 73 (22) | 69 (59-74) | Epirubicin + Cisplatinum + 5-FU or Oxaliplatin + 5-FU or Docetaxel + Oxaliplatin + 5-FU or Other | TG (72.7%) | 91.90% | 22 (100%) | ||||||
| DG (22.7%) | |||||||||||||
P1: Peritoneal carcinomatosis; H1: Hepatic metastases; Cy1: Positive cytology; PAN: Para-aortic node metastases; TG: Total gastrectomy; DG: Distal gastrectomy; DCS/DS: Docetaxel-Cisplatin-S1/Docetaxel-Cisplatin; FEMTXP: Fluorouracil, epirubicin, methotrexate, cisplatin; THP-FLPM: Pirarubicin, 5-FU, Leucovorin, Cisplatin, mitomycin C; FLEP: 5-FU + Leucovorin + Etoposide; CDDP: Cisplatin; DOC: Docetaxel; NS: Not specified.